Bradley M. Turner

university of rochester

H指数:18

被引数:1,224

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Postradiation angiosarcoma of the breast: a 25-year single-institution analysis of clinicopathological characteristics and immunohistochemical biomarker study

放射性乳腺血管肉瘤：一项25年单机构临床病理特征及免疫组织化学标志物研究

BIOTECHNIC & HISTOCHEMISTRY

IF1.4

2026-02-010

PRE

ASO Visual Abstract: Real-world Application of Alliance ACOSOG Z11102: How Many Patients can be Spared Mastectomy?

ASO视觉摘要：Alliance ACOSOG Z11102的实际应用：有多少患者可以避免接受乳房切除术？

Annals of Surgical Oncology

IF3.5

2025-10-190

PRE

Real-World Application of Alliance ACOSOG Z11102: How Many Patients Can be Spared Mastectomy?

联盟ACOSOG Z11102的实际应用：有多少患者可以避免乳房切除术？

Annals of Surgical Oncology

IF3.5

2025-09-160

PRE

ASO Visual Abstract: Biology is Queen—The Oncotype DX 21-Gene Recurrence Score has Stronger Prognostic Ability than Lymph Node Burden for Patients with Breast Cancer

ASO视觉摘要：生物学是女王——Oncotype DX 21基因复发评分比淋巴负荷更能预测乳腺癌患者的预后能力。

Annals of Surgical Oncology

IF3.5

2025-09-050

PRE

Biology is Queen: The Oncotype DX 21-Gene Recurrence Score Has Stronger Prognostic Ability than Lymph Node Burden for Patients with Breast Cancer

生物学是女王：Oncotype DX 21基因复发评分比淋巴结负担更能预测乳腺癌患者的预后能力

Annals of Surgical Oncology

IF3.5

2025-08-200

PRE

Tumor infiltrating lymphocytes in breast cancer: A narrative review with focus on analytic validity, clinical validity, and clinical utility

乳腺癌中的肿瘤浸润淋巴细胞：一篇聚焦于分析有效性、临床有效性和临床应用价值的叙事性综述

Human Pathology

IF2.6

2025-07-020

PRE

Clinical Effect of Pembrolizumab in Uterine Serous Carcinoma May be Affected by HER2 Status and Related Genetic Landscape

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

Impact of HER2 Scoring Criteria on Potential Eligibility for T-DXd Therapy in Uterine Serous Carcinoma

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

HER2-Targeted Treatment in Uterine Serous Carcinoma: Real-World Trastuzumab Use and HER2-Low Expression

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multiinstitutional Cohort Analysis Emphasizing Outcome and Molecular Subtype

MODERN PATHOLOGY

IF5.5

2024-08-010

PRE

HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls

HISTOPATHOLOGY

IF4.1

2024-03-059

PRE

In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry

LABORATORY INVESTIGATION

IF4.2

2024-03-011

PRE

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

CANCER RESEARCH

IF16.6

2023-03-010

PRE

Clinicopathologic Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-institutional Study

MODERN PATHOLOGY

IF5.5

2023-02-013

OAAI

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

HER2-low乳腺癌: 发病率，HER2染色模式，临床病理特征，MammaPrint和蓝图基因组图谱

MODERN PATHOLOGY

IF5.5

2022-08-0171

OAAI

Second-harmonic generation imaging reveals neoadjuvant chemotherapy-induced changes in breast tumor collagen

CANCER RESEARCH

IF16.6

2022-02-150

PRE

The utility of using genomic testing on needle core biopsies during the COVID-19 pandemic: Molecular characterization, risk stratification, neoadjuvant outcome, and future implications

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Clinical risk-assessment, risk-stratification, and outcomes of ER positive, HER2 negative breast cancer patients using the Rochester modified Magee algorithm (RoMMA)

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Clinical-risk assessment of ER positive, Her2 negative breast cancer patients: Correlation between the average modified magee score and mammaprint

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Bradley M. Turner

个人简介

教育背景

工作经历

荣誉奖项

研究方向